# Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Antibiotic Resistant Gram Negative and Positive Bacterial Infections

> **NIH NIH N01** · DYNPORT VACCINE COMPANY, LLC · 2024 · $284,064

## Abstract

The Phase I Clinical Trial Units provide a vehicle for the investigation of new therapeutic and immunomodulatory agents for the treatment of infectious disease.

## Key facts

- **NIH application ID:** 11142290
- **Project number:** 272201500005I-P00009-759302100202-1
- **Recipient organization:** DYNPORT VACCINE COMPANY, LLC
- **Principal Investigator:** GRAIG SHOCKEY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $284,064
- **Award type:** —
- **Project period:** 2021-05-13 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11142290

## Citation

> US National Institutes of Health, RePORTER application 11142290, Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Antibiotic Resistant Gram Negative and Positive Bacterial Infections (272201500005I-P00009-759302100202-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11142290. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*